In an investigation conducted by STEP HFpEF researchers, the potential of semaglutide in targeting heart failure with preserved ejection fraction (HFpEF) related to obesity was explored. A total of 529 adult patients diagnosed with HFpEF and obesity were enrolled in the study and randomly assigned to one of two groups: one receiving once-weekly semaglutide (n=263), and the other receiving a placebo (n=266).
The findings of the study revealed several notable outcomes. Patients who received semaglutide exhibited a more significant improvement in their Kansas City Cardiomyopathy Questionnaire clinical summary scores at the end of 52 weeks in comparison to those who received the placebo. Furthermore, semaglutide was associated with a greater reduction in body weight compared to the placebo group. Additionally, patients administered semaglutide experienced more substantial reductions in their C-reactive protein levels than those on the placebo. Notably, those taking semaglutide also demonstrated more pronounced enhancements in their 6-minute walk distance (6MWD) compared to patients in the placebo group.
Learn more about the interesting studies presented at ESC Congress 2023.